Document is current
Any future updates will be listed below
-
Authors
Tan, Aaron C https://orcid.org/0000-0001-7292-1114
Bagley, Stephen J
Wen, Patrick Y
Lim, Michael
Platten, Michael https://orcid.org/0000-0002-4746-887X
Colman, Howard
Ashley, David M
Wick, Wolfgang
Chang, Susan M
Galanis, Evanthia
Mansouri, Alireza
Khagi, Simon
Mehta, Minesh P
Heimberger, Amy B https://orcid.org/0000-0002-9970-8695
Puduvalli, Vinay K
Reardon, David A
Sahebjam, Solmaz
Simes, John
Antonia, Scott J
Berry, Don
Khasraw, Mustafa https://orcid.org/0000-0003-3249-9849
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03970447 at ClinicalTrials.govnct03193190 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.2005
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
https://doi.org/10.1200/jco-25-01137
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
nct03281369 at ClinicalTrials.govDocuments that mention this clinical trial
259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
https://doi.org/10.1136/jitc-2020-sitc2020.0259
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
nct03280563 at ClinicalTrials.govDocuments that mention this clinical trial
MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).
https://doi.org/10.1200/jco.2024.42.3_suppl.324
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
nct03424005 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
nct03337698 at ClinicalTrials.govDocuments that mention this clinical trial
259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
https://doi.org/10.1136/jitc-2020-sitc2020.0259
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-002015
nct01149083 at ClinicalTrials.govDocuments that mention this clinical trial
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
https://doi.org/10.1136/jitc-2025-011892
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
Documents that mention this clinical trial
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
- License Information
